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The Twin Pillars—Knowledge and Trust
Mark Carlson*
Recent events have raised important questions about
current systems for post-market surveillance and analysis of
pacemaker and implantable cardioverter defibrillator (ICD)
performance and the communication of that performance to
physicians and patients. The Policy Conference on Pacemaker
and Implantable Cardioverter Defibrillator Performance,
convened on September 16, 2005 by the Heart Rhythm Society
and the United States Food and Drug Administration (FDA),
provided an unprecedented opportunity for the major
stakeholders—industry, the FDA, cardiac electrophysiologists,
nurses, and patients—to discuss challenges, concerns, and
opportunities for improvement. Several issues related to
communication of device performance to physicians and to
patients were addressed during the conference. Many of these
issues involved one of two unifying themes: knowledge and
trust. Physicians and patients need to receive timely, accurate,
and understandable information regarding device performance
in order to make appropriate decisions regarding medical care.
Furthermore, patients need to trust that physicians, industry,
and the FDA will always act with the best interests of patients
in mind.
The benefit of pacemakers and implantable defibrillators
has been demonstrated and confirmed by countless clinical
trials. Thousands of lives have been saved and many more
lives have been improved by these devices. But like all
manmade devices, malfunctions in pacemakers and
implantable defibrillators can occur. Timely detection and
communication of malfunctions that have the potential to recur
are critical to patient safety and necessary to improve these
devices.
The conference addressed postmarket surveillance,
analysis, and reporting of device performance information to
©
*

2005 Mark Carlson.
M.D., Case Western Reserve School of Medicine.

177

CARLSON_FINAL_191.DOC

178

01/12/2006 01:10:01 PM

MINN. J.L. SCI. & TECH.

[Vol. 7:1

FDA, physicians, and patients. If one is to identify a device
malfunction, one must first know the expected performance of
the device. It is generally understood that pacemakers and
ICDs, which are powered by lithium batteries, have a certain
“life expectancy” (usually a few years) due to battery depletion;
patients do not expect their devices to function forever. What
may not be well-understood is that these devices, like all
electronic devices, are subject to so-called “random component
failure.” Random component failure is an event that occurs
usually due to chance and is thought to have little or no
likelihood to occur in other devices. The random component
failure rate for pacemakers and ICDs is very low, but it is not
zero.
During the conference, patients clearly expressed that they
desire to understand before implantation the expected
performance and “life expectancy” of their devices, including
the likelihood that components might fail.
Prior to
implantation, physicians routinely counsel their patients on the
risks and potential benefits of the procedure and the therapy
and often discuss expected battery longevity.
Additional
information regarding device longevity and performance could
be provided in written form by the manufacturer and could be
conveyed to the patient as part of the pre-procedure consent
process.
Postmarket surveillance is critical to timely identification
of potential device malfunctions and precise reporting of device
performance.
FDA uses passive surveillance (including
mandatory and voluntary event reporting and annual reports),
enhanced surveillance (through the Medical Product
Surveillance Network (MedSun)), and observational studies
(both required and discretionary) to accomplish this task.
Passive surveillance relies on the return of devices after
explantation or death for analysis, particularly when a
malfunction is known or suspected. However, industry reports
that only a fraction of pacemakers and ICDs are returned.
Increasing the fraction and absolute number of devices that are
returned for analysis would enhance the surveillance process
significantly and would have beneficial effects downstream in
the process.
Physicians,
nurses,
morticians,
manufacturer
representatives, and patients and their families play an
important role in returning devices that provide useful
information. Some may be unaware of the importance of
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returning the device even when it appears that it has
performed very well. Others may not be aware of what must be
done to return a device properly. The handling of a device after
it is removed can affect the quality of the data available for
analysis. Removing an active device or cutting the leads when
a device is active can corrupt the stored data and make it
difficult to assess device performance.
Educational programs may improve the rate of return and
the quality of the information that is available for analysis. All
of the relevant parties should understand the importance of
returning these devices and the process for doing so. Those
who remove devices (physicians and morticians) should
understand how to do so properly in order to retain as much
data as possible.
Additional options to enhance surveillance include the use
of current and new databases, new electronic remote
monitoring capabilities, and incentives or regulatory
requirements. Countries with some of the highest return rates,
like Denmark, provide financial incentives to physicians and
patients to return devices; payment of medical bills depends on
return of the device.
Providing similar incentives or
requirements for return of devices in the United States would
constitute a major change in public policy.
The current system for surveillance and analysis of
pacemaker and ICD performance relies to a significant extent
on the manufacturers who receive and analyze information and
devices from the field and report findings to the FDA,
physicians, and patients. Although FDA has some ability to
discover findings independently, the system depends on the
manufacturer acting in the best interest of all to identify and
report significant device problems accurately and in a timely
fashion. As was pointed out in the policy conference, it is in the
manufacturer’s best long-term interest to do so. However, it
was also noted that manufacturers could encounter
disincentives, primarily short-term financial ones, to disclose
such information. For instance, it was noted that the discovery
of a significant problem in a device with considerable unsold
inventory could affect a manufacturer’s expected revenue
dramatically.
Furthermore, disclosure of potential
malfunctions is not welcome news to investors and can affect
stock prices adversely.
Industry has used certain practices that limit these
potential conflicts and other practices might be considered.
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When a potential device malfunction is identified,
manufacturers often convene a group of physician experts to
discuss the implications, suggest the best approach to
mitigation, and communicate information to physicians and
patients. Some have suggested that an independent group of
experts could serve industry and the FDA for all such
circumstances. Others have suggested that an independent
body, such as the underwriters’ laboratory, might be bestsuited to collect, analyze, and report information on device
performance. However, some believe that such an approach
would be costly, burdensome, and problematic, given, among
other things, the proprietary information associated with many
devices. They believe that the manufacturer is best-positioned
to analyze and make adjustments in devices and that only
minor, if any, adjustments to the current system are required.
Patients and physicians have expressed the desire for
certainty which might be achieved by standardizing certain
communication processes. Several expressed the desirability of
identifying triggers for notifying physicians and patients of a
potential for device malfunction. These triggers could be based
on the objective risk level (for example, 1/1000 or 1/5000
incidence) or the subjective risk level (such as the potential
impact of the malfunction on the patient’s health). One
problem with triggers based on objective risk level is that
people do not agree on what likelihood of event occurrence
constitutes an acceptable risk; neither physicians nor patients
appear to agree on the risk level at which notification should
occur. Furthermore, basing the trigger on objective risk alone
does not account for the variable impact on health of different
device malfunctions. Another approach is to base triggers for
notification on the potential impact of the malfunction on
patients’ health. Such a trigger would need to account for the
variable impact that some malfunctions may have between
patients. It seems clear that both the objective and subjective
risks must be considerations in any system, and that some
uncertainty will exist for individual patients. In the end,
patients may be willing to accept some uncertainty if they can
trust that under certain circumstances they, and their
physicians, will be notified of a potential device malfunction.
Patients and physicians have also expressed the desire for
standardized device performance reports. Opportunities exist
for standardization among manufacturers of annual reports
and notifications of device malfunction that could enhance the
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interpretation of the information.
Reports could include
similar information and display that information in a common
format. It has been recognized however, that differences in
devices and potential malfunctions make standardized
reporting a challenging goal.
Furthermore, patients and physicians have expressed the
desire to better understand the terms that are used when
notified of a potential device malfunction. Many patients do
not understand medical device recall terminology, the different
types of recalls, or the implications of these terms for medical
care. The term “recall” can cause unnecessary concern and
confusion because the implications of the term when used for
non-medical products can be significantly different than when
the term is used for a pacemaker or implantable defibrillator.
Moreover, it is not clear that patients thoroughly understand
the differences in recall classification: class I for potential
malfunctions that are life-threatening and class II for potential
malfunctions that are not life-threatening. Revision of the
current terminology is no simple task because it is stipulated in
the federal code. In the short term, patients may benefit from
education regarding the meaning and medical implications of
these terms.
Patients want to hear from their physicians when a
potential malfunction in their device is reported. Physicians
would prefer that their patients heard from them first. FDA
and industry have traditionally communicated with patients
through their physicians. However, in an environment where
information can be shared “real time” through the media and
the Internet, and publicly traded companies are required to
share information quickly with investors, patients often do not
learn of a potential device malfunction from their physicians.
This situation is not likely to change unless medical electronic
information systems and communication systems become much
more robust. New remote monitoring technology might provide
opportunities for rapid patient communication in the future.
Until then, patients and physicians should expect that they
may sometimes learn of device problems through sources other
than the FDA or industry. Nonetheless, patients should
consult their physicians to understand the implications of any
potential malfunction for their medical care.
Indeed, the implications of a potential device malfunction
may vary greatly among patients. For instance, sudden loss of
pacing could be life-threatening in a patient without an
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underlying heart rhythm but completely inconsequential in a
patient with an ICD who has no risk for a slow heart rhythm.
The recommended actions for these two patients might be quite
different.
Furthermore, patients need to understand the
potential consequences (risks and benefits) of the actions that
they might take to mitigate the risk of a potential device
malfunction. Replacing a pacemaker or defibrillator lead or
pulse generator can entail risk and in some cases that risk may
be greater than the risk associated with the potential
malfunction.
Here too, the risk associated with device
replacement may vary significantly between patients.
A
patient’s physician is best qualified to understand these issues
and provide appropriate advice.
But the physician is not the only source of information
from which patients wish to hear. Patients have stated that
they want to receive information from the manufacturer and
from FDA. Some patients value the opportunity to talk directly
with their physician and the device manufacturer
representative simultaneously.
In certain cases, some
physicians have invited their patients to meet with them and
an industry representative in an open forum.
Patients,
physicians, and the industry representatives have found that
this open dialogue enhances communication and helps to
maintain trust.
The Device Performance Policy Conference provided an
opportunity for open dialogue among patients, physicians,
industry, and government that was unprecedented.
The
conference provided a clearer understanding of the complex
surveillance, analysis, and communication processes and the
opportunities for improvement. The knowledge that was
shared benefited all involved and provided a basis for next
steps. Perhaps the most crucial lesson learned during the
conference was the importance that the FDA, device
manufacturers, and physicians collaborate to improve the
system. Patients are depending on us to continue to work
together and to place their interests first. Only by doing so will
patients trust their devices and those of us who are responsible
for their medical care.

